I have been fortunate to get involved in biological crop protection from the beginning of this sector's rapid expansion with hands-on product development, market strategy, and commercial development experience. I have a deep understanding of what it takes to be successful in biologicals.
As Director of Business & Product Development for North America my team was responsible for gaining access to biological technologies then developing them. Some of our key successes are below.
FMC acquired CAEB (Center for Ag and Environmental Biosolutions) from RTI where we gained access to thousands of strains of biofungicides, bioinsecticides, biostimulants, and soil amendments.
While at FMC we entered into a strategic partnership with fermentation world leader Chr. Hansen as our manufacturing arm who I got to interact with on a regular basis.
While at AMVAC I developed the initial business platform for our global biologicals business collaborating with our regional businesses to identify an initial portfolio of biostimulants, biochemicals, biopesticides, and soil amendments.
While at FMC I gained access to bacillis amyloliquefaciens BAD 747 that my team developed in a premix formulation with bifenthrin - the leading at plant soil insecticide for the first-ever hybrid biological/synthetic product in the industry providing at plant control of insects and diseases
I gained access to our first plant extract (lupine bean) biofungicide Problad from CEV and our team of PDMs developed it for commercialization in grapes, strawberries, and almonds for the control of powdery mildew, botrytis, and brown spot.
Worked with Ascribe BioScience to develop commercial development for Phytalix small molecule biofungicide.
Consulted for Andermatt to assess the US opportunity for a product they are selling in Europe.
Developed a robust assessment of opportunities to expand the portfolio for Certis Bilogicals.
At FMC our team of PDMs conducted hundreds of field trials annually developing protocols, viewing results, and developing trial summaries to report to the global team.
Collaborating with partners, CROs, universities, and other functions while managing the project management process and leading quarterly project reviews resulted in the successful development of a bilogical pipeline.
Consulted with The Context Network to develop our multi-client Global Biologicals Report assessing market indication metrics, segments, regions, company profiles, technologies, and challenges. This report was updated bi-annually and purchased by several leading biological companies.
Regularly attend industry conferences, subscribe to newsletters, connect with my network to stay current with the ever-evolving biological segment.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.